Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders
Abstract
Background Obesity is associated with musculoskeletal disorders, impaired mobility, and frailty. While semaglutide induces substantial weight loss, its effects on objectively measured physical function in routine clinical practice are unclear. We investigated the changes in gait speed and physical function during a multidisciplinary obesity management program that included semaglutide.Methods This retrospective observational study included 22 adults with obesity and musculoskeletal disorders who completed a 12-month multidisciplinary obesity management program. The program included nutritional counseling every two months, physical therapist-guided exercise intervention, and semaglutide treatment. The primary outcome was the usual gait speed. The secondary outcomes included body weight, pain score, step count, muscle function, and body composition.Results Body weight decreased significantly from 89.2±18.6 kg to 81.5±17.3 kg (p<0.001). Usual gait speed improved significantly from 0.77±0.20 m/s to 0.91±0.19 m/s (p<0.001). Pain scores also significantly improved (p<0.001). Improvements in gait speed were not associated with weight loss (r=0.22, p=0.32) or pain reduction (r=-0.04, p=0.84). Baseline gait speed was inversely associated with gait speed improvement (r=-0.44, p=0.043), indicating greater gains in participants with poorer baseline mobility.Conclusions A 12-month multidisciplinary obesity management program, including semaglutide, significantly improved gait speed in patients with obesity and musculoskeletal disorders. Greater improvements were observed in participants with impaired baseline mobility. These findings support the evaluation of obesity treatment not only by weight loss, but also by recovery of mobility.
Related
- Musculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting System.
- Direction of discordance between PET/CT, EBUS-TBNA, and multidisciplinary tumor board nodal assignment in non-small cell lung cancer : A retrospective observational study
- Advances in pharmacologic management of obesity: oral semaglutide for weight management
- Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective study
- Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study
BibTeX
@article{tomita2026changes,
title = {{Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders}},
author = {Masuomi Tomita and Fumiya Harashima and Naoto Takeda and Chikako Ishida and Kazuhito Nagasaki and Kyota Kikuchi and Katsuya Hisamichi},
journal = {Internal Medicine},
year = {2026},
month = oct,
doi = {10.2169/internalmedicine.8145-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8145-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders
AU - Masuomi Tomita
AU - Fumiya Harashima
AU - Naoto Takeda
AU - Chikako Ishida
AU - Kazuhito Nagasaki
AU - Kyota Kikuchi
AU - Katsuya Hisamichi
PY - 2026
DA - 2026/10/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.8145-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_8145-26/_article
AB - Background Obesity is associated with musculoskeletal disorders, impaired mobility, and frailty. While semaglutide induces substantial weight loss, its effects on objectively measured physical function in routine clinical practice are unclear. We investigated the changes in gait speed and physical function during a multidisciplinary obesity management program that included semaglutide.Methods This retrospective observational study included 22 adults with obesity and musculoskeletal disorders who completed a 12-month multidisciplinary obesity management program. The program included nutritional counseling every two months, physical therapist-guided exercise intervention, and semaglutide treatment. The primary outcome was the usual gait speed. The secondary outcomes included body weight, pain score, step count, muscle function, and body composition.Results Body weight decreased significantly from 89.2±18.6 kg to 81.5±17.3 kg (p<0.001). Usual gait speed improved significantly from 0.77±0.20 m/s to 0.91±0.19 m/s (p<0.001). Pain scores also significantly improved (p<0.001). Improvements in gait speed were not associated with weight loss (r=0.22, p=0.32) or pain reduction (r=-0.04, p=0.84). Baseline gait speed was inversely associated with gait speed improvement (r=-0.44, p=0.043), indicating greater gains in participants with poorer baseline mobility.Conclusions A 12-month multidisciplinary obesity management program, including semaglutide, significantly improved gait speed in patients with obesity and musculoskeletal disorders. Greater improvements were observed in participants with impaired baseline mobility. These findings support the evaluation of obesity treatment not only by weight loss, but also by recovery of mobility.
SN - 1349-7235
SN - 0918-2918
ER -